Ocrelizumab is a humanized monoclonal anti-CD20 antibody approved for treatment of relapsing-remitting and primary progressive multiple sclerosis (MS). Rare parasitic infections have been reported in patients with lymphoproliferative disorders using rituximab, a chimeric anti-CD20 antibody used off-label for the treatment of MS. Here, we report a patient with MS on ocrelizumab with B-cell depletion who developed severe Babesia microti (B. microti) infection with neutropenia, hemolytic anemia, and thrombocytopenia. He recovered after prompt diagnosis and treatment. This case represents the first published occurrence of babesiosis in a patient with MS on ocrelizumab. It also adds to the accumulating evidence from databases of emergent severe or relapsing B. microti infection in patients receiving anti-CD20 antibodies. This presentation stresses the diagnostic vigilance required by MS neurologists in endemic areas to identify cases of babesiosis in patients on anti-CD20 therapy and to better counsel these individuals on their risks of B. microti infection. Report data on acoustic measures of voice in sustained vowels produced by typically developing children, aged 4-19 years, to add to the cross-sectional reference values in a pediatric database. Recordings of sustained vowel/ɑ/phonation were obtained from 158 children (80 males, 78 females) aged 4-19 years who were judged to be typically developing with respect to speech and voice. Rogaratinib Acoustic analyses were performed with the Multidimensional Voice Program (MDVP™) and the Analysis of Dysphonia in Speech and Voice (ADSV™), both from Pentax Medical. Values from both MDVP and ADSV are reported for children in the following age cohorts 4-6 years, 7-9 years, 10-12 years, 13-15 years, and 16-19 years. The data in this study complement previously published data and contribute to a pediatric reference database useful for research and for clinical practice related to children's voice. Acoustic parameters most sensitive to age and sex are identified.The data in this study complement previously published data and contribute to a pediatric reference database useful for research and for clinical practice related to children's voice. Acoustic parameters most sensitive to age and sex are identified.Compressed sensing (CS) has been adapted to synthetic aperture (SA) ultrasound imaging to improve the frame-rate of the system. Recently, we proposed a novel CS framework using Gaussian under-sampling to reduce the number of receive elements in multi-element synthetic transmit aperture (MSTA) imaging. However, that framework requires different receive elements to be chosen randomly for each transmission, which may add to practical implementation challenges. Modifying the scheme to employ the same set of receive elements for all transmissions of MSTA leads to degradation of the recovered image quality. Therefore, this work proposes a novel sampling scheme based on a genetic algorithm (GA), which optimally chooses the receive element positions once and uses it for all the transmission of MSTA. The CS performance using GA sampling schemes is evaluated against the previously proposed CS framework on in-vitro and in-vivo datasets. The obtained results suggest that not only does the GA-based approach allows the use of the same set of sparse receive elements for each transmit, but also leads to the lowest CS recovery error (NRMSE) and 14% overall improvement in image contrast, in comparison to the previously-proposed Gaussian sampling scheme. Thus, using the CS framework along with GA, can potentially reduce the complexity in implementation of CS-framework to MSTA based systems. This study aimed to describe the electroclinical spectrum and neurocognitive outcome in children with epileptic encephalopathy with status epilepticus during sleep (ESES) according to the EEG patterns. Records of 48 (19 males, 29 females) patients with ESES/CSWS syndrome were retrospectively evaluated for data on sleep and awake EEGs, psychometric tests, and brain MRI. Patients with a spike-wave index (SWI) of at least 50 % in the NREM sleep EEG were included in the study. Electrophysiologic findings were separated into two groups based on SWI SWI>85-100 % (typical ESES) and SWI < 85 % (atypical ESES). The neurocognitive prognosis was also evaluated in two groups; favorable and unfavorable. The median age at the onset of ESES was 6 years and 5 months and ranged from 3 to 13 years. The median duration of follow-up after the ESES diagnosis was 57 months (range 24-150 months). Etiology was evaluated in three groups symptomatic/structural, idiopathic, and unknown (cryptogenic). Twenty-seven (56.25 %) is exceedingly variable. An unfavorable neurocognitive outcome seems to be related to ESES with a long-duration and early-onset epileptic activity, SWI ≥ 85 %, and etiology. The aim of this study was to assess the usefulness of perampanel (PER), and to identify the relationship between behavioral impairments and electroencephalogram (EEG) findings in epilepsy patients with autism spectrum disorder (ASD). Participants were ASD patients with epilepsy recruited between June 1, 2016 and June 30, 2018. Inclusion criteria were seizures refractory to two appropriate antiseizure medications (ASMs); presence of neuropsychological impairments; and ≥12 months of monitoring. PER was administered once daily, starting at a dose of 2 mg/day, increased to 12 mg/day. Seizure/EEG responders were identified as participants showing a >50 % reduction in seizure/interictal epileptiform discharge (IED) frequency (indicated as complete disappearance and response). Behavioral responders were identified as participants with a ≥50 % reduction in scores of the Japanese manuals for the Aberrant Behavior Checklist (ABC-J). Eleven (64.7 %) of 17 patients were considered to be both seizure and EEG resp improvement in at least some ASD patients.The results from this study suggest the utility of PER treatment in reducing clinical seizures and IEDs for ASD patients with intractable epilepsy, at least in some patients. Moreover, the present results also indicate the usefulness of PER in improving neuropsychiatric impairments, including behavioral disturbances in ASD related to improvement of clinical seizures/frontal IEDs, but also unrelated to seizure/EEG improvement in at least some ASD patients.